Key Technology, a US manufacturer of process automation systems, has promoted Bret Larreau to the new position of manager of business development. He takes responsibility for building new business alliances and developing acquisition opportunities that will expand Key’s solutions within the pharmaceutical and food manufacturing industries.
Larreau has been with Key Technology for eight years and brings 25 years of automated food processing equipment experience to his position. Prior to this promotion, he was the product marketing manager responsible for Key’s optical sorters.
Before joining Key, he was a senior project manager for Integrated Packaging Systems and prior to that, he worked in engineering, manufacturing management, sales support management and product management for DSI/Stein, part of FMC FoodTech.
‘It’s exciting to make this shift, leveraging my experience in the industry and recent market development activities, to focus on finding new opportunities to improve customers’ operations and grow Key’s business,’ said Larreau.
‘We’ve the resources and the personnel to make new partnerships, acquisitions, and licensing a high priority, while continuing to work closely with existing partners on ongoing projects.’
Key Technology makes a promotion
Bret Larreau becomes manager of business development
You may also like
Manufacturing
Buckland Group launches Quvara Medical after acquiring Becton Dickinson’s Swindon site to boost UK-EU medical manufacturing
The acquisition establishes Quvara Medical as a new UK- and EU-based CMO offering GMP- and ISO-certified, high-volume manufacturing services to pharma and medtech clients
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Rentschler Biopharma and Coriolis Pharma partner to deliver integrated biopharma development and manufacturing solutions
The German-based CDMO and CRDO will offer unified formulation-to-manufacturing services to accelerate biologics development. The collaboration aims to cut complexity, timelines and risk for global biopharma clients